Company intelligence / Profile preview

Sio Gene Therapies

New York City, NY, USAsiogtx.com ↗

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Sio reported positive interim safety and biomarker data from its ongoing Phase 1/2 study of AXO-AAV-GM1 in GM1 gangliosidosis, showing dose-dependent improvements and normalization of key biomarkers. No serious adverse events attributable to the therapy were observed. The company also advanced manufacturing capabilities for its AXO-Lenti-PD program in Parkinson's but did not reach pivotal or commercial stages before winding down operations.

Therapeutic areas: Rare DiseasesNeurology
Modalities: AAV-based gene therapy (Adeno-associated virus vectors)Lentiviral vector gene therapy
Industry: Biotech

Drug pipeline

8 assets

AXO-AAV-FTD

Preclinical

7 more assets in the full pipeline.

Partnerships

Oxford BioMedica (manufacturing collaboration for AXO-Lenti-PD)UMass Chan Medical School (licensed rights to GM1 & GM2 programs)

Beyond the preview

Go deeper on Sio Gene Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sio Gene Therapies.